BioCentury
ARTICLE | Company News

QIDP for Motif's iclaprim triggers L22M placing

July 18, 2015 12:10 AM UTC

FDA granted Qualified Infectious Disease Product (QIDP) designation to iclaprim from Motif Bio plc (LSE:MTFB) to treat hospital-acquired bacterial pneumonia (HABP), triggering a L22 million ($34.1 million) placing. Motif sold 44 million shares at 50p to institutional investors including Aviva; Invesco; and Standard Life. Zeus Capital and Northland Capital Partners were joint brokers.

The company said it expects FDA to grant QIDP designation to iclaprim for acute bacterial skin and skin structure infections (ABSSSI) "within the next few days." ...